Supplementary Materials1. RNAs that are part of the spliceosome were recently identified16. However, splicing abnormalities found in cancer are not always associated with mutations in these or related genes. Instead, they may arise from aberrant expression of splicing factors17C26. Certain serine/arginine-rich (SR) splicing factor proteins are overexpressed in human cancers, notably SRSF117C20,26, SRSF617,21,22, and SRSF323C25. Part of this activation might be due to gene amplification as well as transcriptional regulation, mainly through MYC. Expression-related variations in splicing are mostly observed in solid tumors of adult origin, suggesting a potential explanation for differences in splicing biology between solid and blood-based cancers. Acute lymphoblastic leukemia (ALL) is an aggressive pediatric and adult type of leukemia of T- and B-cell origin translating to approximately 3,100 children and adolescents are diagnosed with the disease each year in the United States. T-cell ALL (T-ALL) is driven by the hyperactivation of pathways such as NOTCH127C32 and the incidence of this disease subtype is increasing33. One-fifth of pediatric patients and more than 50% of adult patients with T-ALL do not achieve a complete remission or relapse after consolidated chemotherapy, making resistance to therapy the most substantial challenge in disease treatment31,34,35. T-ALL is an epigenetic disease presenting with deregulation of epigenetic enzymes. As many KIT T-ALL oncogenes are transcription factors, disease initiation and progression are coordinated via epigenetic regulators in the cell nucleus. Work by our lab and others have described the major epigenetic players in this disease27,28,36C47. However, the design of treatment strategies based on direct inhibitors of these proteins has been challenging, as oncogenes such as NOTCH1 are broadly involved in physiologic processes. Furthermore, there are very few documented mutations affecting splicing factors in T-ALL48, and the splicing landscape in T-ALL is relatively poorly characterized. Thus, as of this writing, we lack evidence-based strategies for treating cancers like T-ALL that have no or very few splicing factor mutations. In addition, ITK Inhibitor mechanisms of resistance in T-ALL remain poorly characterized due to ITK Inhibitor the absence of appropriate leukemia models and needed technologies. Although we and others have previously demonstrated the role of epigenetic factors and oncogenic long non-coding RNAs in T-ALL41C43, the role of aberrant splicing and mechanisms of abnormal post-translational regulation of the splicing machinery in T-ALL progression have been relatively uncharacterized. In this study, we sought to characterize splicing alterations in T-ALL, potential ITK Inhibitor mechanisms regulating aberrant splicing, and their implications for T-ALL biology. RESULTS T-ALL is ITK Inhibitor characterized by significant splicing changes compared to physiological T cells To characterize the splicing landscape in different types of human peripheral CD3+ (CD4+/CD8+) T cells, in comparison to three T cell leukemia patients, we performed paired-end sequencing of the transcriptome to cover the splicing junctions. To study any T cell subtype-specific and differentiation stage-specific phenomena we also included a T cell subtype, CD4+ T cells, and undifferentiated fast-proliferating thymocytes. Initial expression analysis of normal and tumor samples using edgeR49 showed a significant up-regulation of oncogenic targets in T-ALL, including NOTCH1 targets, as well as cell cycle regulators, in agreement with previous findings in human and mouse contexts of T-ALL41 (Fig 1A and Supplementary Fig. 1ACD, Supplementary Tables 1C3). We then used rMATS50, an established method for quantitative analysis of differential splicing phenomena, to cluster splicing changes between peripheral CD3+ T cells and T-ALL, in five distinct categories: exon skipping, intron retention, mutually exclusive exons, and usage of alternative 3 or alternative 5 splice sites (Fig. 1B and Supplementary Fig. 1E). We observed changes for each of these splicing categories between the two cell populations, with the most extensive splicing changes affecting skipped exons and retained introns (Fig. 1B, ?,CC and Supplementary Figs. 1E, 2A, B). Overall, there was a significant increase of exon skipping events in T-ALL cells compared to normal T cells (see red bar representing excluded exons, Fig. 1C). An alternative analysis quantifying exon inclusion levels and comparison of normal T cell subsets with T-ALL patients showed there are more exon inclusion phenomena in T cells compared to T-ALL (Supplementary ITK Inhibitor Fig. 2C). In conclusion, T cell cancers present with a higher number of skipped exon phenomena compared to physiological T cells. Open in a separate windowpane Fig. 1. Considerable changes in exon skipping phenomena in T-ALL compared to physiological T cells.A, Heatmap of gene manifestation changes representing 630 significantly up-regulated genes and 531 down-regulated genes in T-ALL patient samples compared to CD3+ T cells, ranked based on manifestation level in T-ALL ( 0.05). E, Kyoto Encyclopedia of Genes and Genomes (KEGG) analysis showing main transcript pathways enriched in splicing events in T-ALL compared to CD3+ T cells. Transcript groups are.